Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects DOI Creative Commons
Prashant Tiwari, Anis Ahmad Chaudhary, Saurabh Gupta

et al.

Frontiers in Molecular Biosciences, Journal Year: 2025, Volume and Issue: 12

Published: April 14, 2025

Breast cancer (BC) remains a complex and widespread problem, affecting millions of women worldwide, Among the various subtypes BC, triple-negative breast (TNBC) is particularly challenging, representing approximately 20% all BC cases, survival rate TNBC patients generally worse than other BC. heterogeneous disease characterized by lack expression three receptors: estrogen (ER), progesterone (PR), human epidermal growth factor receptor 2 (HER2), resulting conventional hormonal therapies are ineffective for its management. Despite therapeutic approaches have been explored, but no definitive solution has found yet TNBC. Current treatments options chemotherapy, immunotherapy, radiotherapy surgery, although, these some limitations, such as development resistance to anti-cancer drugs, off-target toxicity, which remain primary obstacles significant challenges Several findings shown that EVs exhibit promise in many diseases, similar important role observed types tumor. Studies suggest may offer potential management This review highlights multifaceted roles TNBC, emphasizing their involvement progression, diagnosis approach, well biomarkers drug delivery.

Language: Английский

Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects DOI Creative Commons
Prashant Tiwari, Anis Ahmad Chaudhary, Saurabh Gupta

et al.

Frontiers in Molecular Biosciences, Journal Year: 2025, Volume and Issue: 12

Published: April 14, 2025

Breast cancer (BC) remains a complex and widespread problem, affecting millions of women worldwide, Among the various subtypes BC, triple-negative breast (TNBC) is particularly challenging, representing approximately 20% all BC cases, survival rate TNBC patients generally worse than other BC. heterogeneous disease characterized by lack expression three receptors: estrogen (ER), progesterone (PR), human epidermal growth factor receptor 2 (HER2), resulting conventional hormonal therapies are ineffective for its management. Despite therapeutic approaches have been explored, but no definitive solution has found yet TNBC. Current treatments options chemotherapy, immunotherapy, radiotherapy surgery, although, these some limitations, such as development resistance to anti-cancer drugs, off-target toxicity, which remain primary obstacles significant challenges Several findings shown that EVs exhibit promise in many diseases, similar important role observed types tumor. Studies suggest may offer potential management This review highlights multifaceted roles TNBC, emphasizing their involvement progression, diagnosis approach, well biomarkers drug delivery.

Language: Английский

Citations

0